A randomised placebo-controlled clinical trial investigating the neurocognitive effects and in vivo mechanisms of action of Lacprodan(Registered Trademark) PL-20 in elderly participants with age-associated memory impairment.

Swinburne University of Technology0 sites138 target enrollmentStarted: April 2, 2013Last updated: January 13, 2020

Conditions

Trial Snapshot

No summary available.

•Male or female.
•-Aged >55 years.
•-Meets diagnostic criteria for age-associated memory impairment: AAMI is defined on the basis of criteria first outlined by Crook et al: (i) A score >25 on the Memory Complaint Questionnaire (MAC-Q) and (ii) a score at =1 standard deviation below the mean for healthy young adults on the Paired Associates Test from the Wechsler Memory Scale - Revised (WMS-R)
•-Willing and able to provide written informed consent.
•-Understands and is willing and able to comply with all study procedures.
•-English speaking.
•-Normal or corrected vision.
•-Must be right-handed (applies only to the neuroimaging sub-study).

•Dementia and/or MMSE score <24.
•Neurological, cardiac, endocrine, gastrointestinal or bleeding disorders.
•Psychiatric illness including mood disturbance/depression, as confirmed with a BDI-II >=20.
•History of alcoholism and/or substance abuse.
•Any known or suspected allergy to cow’s milk and/or lactose intolerance.
•Participation in another clinical trial during the past 2 months.
•Using any medications that could affect the outcome of the study including any pharmacological agents with known cognitive effects and diabetic medications.
•Taking vitamins or herbal supplements regularly.

Sponsor